ValiRx PLC
("ValiRx" or the "Company")
Notice of Results and Investor Webinar
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, will be announcing its audited results for the year ended 31 December 2022 on Monday 5 June 2023.
A presentation to shareholders and Q&A sessions will be held at the Company's laboratory site in Nottingham on Wednesday, 14 June 2023.
Shareholders are invited to register for a place to attend by emailing the CEO on the details provided below; however, as capacity is limited, registration will be assigned to be either physical or virtual, with virtual attendees provided a link to watch the event via webinar. The webinar will be available to view on demand through our website after the event.
The Directors of the Company take responsibility for this announcement.
For more information, please contact:
|
ValiRx plc Dr Suzanne Dilly, CEO |
Tel: +44 (0) 2476 796496 |
|
V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director |
+44 (0) 115 787 0206 lucy@vformation.biz sue@vformation.biz |
|
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
|
Cenkos Securities plc (Joint Broker) Dale Bellis/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance) |
Tel: +44 (0) 20 7397 8900 |
|
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker |
Tel: +44 (0) 20 3657 0050 |
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com